DDB2 Suppresses Epithelial-to-Mesenchymal Transition in Colon Cancer

Nilotpal Roy1, Prashant V. Bommi2, Uppoor G. Bhat1, Shaumick Bhattacharjee1, Indira Elangovan1, Jing Li1, Krushna C. Patra1, Dragana Kopanja1, Adam Blunier3, Richard Benya3, Srilata Bagchi2, and Pradip Raychaudhuri1

Abstract
Colon cancer is one of the deadliest cancers worldwide because of its metastasis to other essential organs. Metastasis of colon cancer involves a complex set of events, including epithelial-to-mesenchymal transition (EMT) that increases invasiveness of the tumor cells. Here, we show that the xeroderma pigmentosum group E (XPE) gene product, damaged DNA-binding protein (DDB)-2, is downregulated in high-grade colon cancers, and it plays a dominant role in the suppression of EMT of the colon cancer cells. Depletion of DDB2 promotes mesenchymal phenotype, whereas expression of DDB2 promotes epithelial phenotype. DDB2 constitutively represses genes that are the key activators of EMT, indicating that DDB2 is a master regulator of EMT of the colon cancer cells. Moreover, we observed evidence that DDB2 functions as a barrier for EMT induced by hypoxia and TGF-β. Also, we provide evidence that DDB2 inhibits metastasis of colon cancer. The results presented here identify a transcriptional regulatory pathway of DDB2 that is directly linked to the mechanisms that suppress metastasis of colon cancer. Cancer Res; 73(12); 1–12. ©2013 AACR.

Introduction
Epithelial-to-mesenchymal transition (EMT) is a conserved developmental process that is usurped often by epithelial tumors during metastatic progression. Several oncogenic pathways activated by Src, Ras, Ets, Integrin, Wnt, Notch, hypoxia, and TGF-β signaling have been shown to induce EMT (1, 2). Moreover, a number of EMT-inducing transcriptional regulators such as Snail1, Slug, Twist, Zeb1, and Zeb2, which are downstream of the aforementioned signaling pathways, have been characterized (3–9). These transcriptional regulators inhibit expression of E-cadherin, which is considered to be a key event in EMT (3). For example, the TGF-β effectors Smads associate with the Zeb proteins to repress expression of E-cadherin (9–13). TGF-β and Wnt/β-catenin–mediated EMT also involves activation of Snail1, which represses expression of E-cadherin (3, 10, 14, 15). Likewise, the hypoxia-activated transcription factor, hypoxia-inducible factor-1 induces EMT by activating expression of Twist, Snail, and VEGF-A (16–19). Moreover, extracellular matrix degrading matrix metalloproteinases also have been found to alter intracellular signaling pathway to initiate the EMT process (20). Thus, the pathways that lead to an activation of the EMT-inducing transcription factors (Snail1, Zeb1, Zeb2, and Twist) have been characterized, and they have been implicated in metastasis of the epithelial tumors. However, except for some miRNA studies, the regulators that inhibit expression of the EMT-inducing transcription factors in the epithelial tumor cells and block mesenchymal transition remain poorly understood.

Damaged DNA-binding protein (DDB)-2, a protein encoded by the nucleotide excision repair (NER) gene, xeroderma pigmentosum group E (XPE), is a multifunctional protein (21, 22). Several studies indicated a role of DDB2 in remodeling damaged chromatin in the early steps of NER (21). However, in normal mouse fibroblasts and keratinocytes, the NER function of DDB2 is related to the regulation of the cell-cycle inhibitor p21 because deletion of p21 reversed the repair deficiency in the DDB2−/− cells (23). Proteolysis of p21 is inefficient in the DDB2−/− cell, and that causes accumulation of high levels of p21 following DNA damage (23). It is possible that the chromatin remodeling activity of DDB2 is linked to the mechanism by which it induces proteolysis of p21 after DNA damage. DDB2 associates with Cul4-DDB1 E3 ligase and functions as a substrate adapter for that ligase (24, 25). In addition to NER, DDB2 is involved in DNA damage-induced apoptosis. High-level accumulation of p21 in the DDB2-deficient cells was found...
to be the cause of the deficiency in apoptosis. Deletion of p21 in the DDB2−/− background reversed the apoptosis deficiencies of the DDB2−/− cells (26, 27).

Interestingly, the DDB2−/− cells are deficient also in premature senescence (28). The deficiency in senescence results from a lack of reactive oxygen species (ROS) accumulation (28). Studies on the mechanism indicated a distinct role of DDB2 in transcriptional repression. DDB2 represses expression of the antioxidant genes, Sod2 (29) and Catalase, to allow persistent accumulation of ROS and thereby induces premature senescence (28). In this study, we explain the functional significance of the loss of DDB2 expression in high-grade colon cancers and reveal a novel role of DDB2 as a constitutive repressor of the EMT-inducing transcription factors in colon cancer.

Materials and Methods

Immunohistochemistry/immunofluorescence

Tumor sections were processed for immunohistochemistry, as described before (27). The sections were incubated with the DDB2, proliferating cell nuclear antigen (PCNA), or smooth muscle actin (SMA) antibody 1:200 dilution overnight, and then washed 3 times with 1× PBS and incubated with anti-mouse/rabbit AP (VectorLabs AP-2000) and further developed with Alkaline Phosphatase Substrate (VectorLabs SK-5300) following manufacturer’s protocol. Nuclei were counterstained with hematoxilin. For immunofluorescence of the mouse tumor sections, blocking was conducted using 5% horse serum in PBS for 1 hour at room temperature. Sections were incubated overnight at 4°C using following primary antibody. After washing with PBS, sections were incubated with anti-rabbit/anti-mouse immunoglobulin conjugated with fluorescein isothiocyanate/tetramethyl rhodamine 5-6 Isothiocyanate.

For immunofluorescence of cells, permeabilized cells were incubated with E-cadherin (1:250), vimentin (1:200), or SMA (1:200) antibody overnight. Cells were washed for 5 times with PBS followed by incubation with fluorescein isothiocyanate/tetramethyl rhodamine 5-6 Isothiocyanate-tagged goat anti-rabbit antibody (1:500) for 1 hour at room temperature. Cell nuclei were labeled with 4′, 6-diamidino-2-phenylindole in PBS for 5 minutes at room temperature. After a final wash with PBS, cells were mounted on slides and photographed under microscope.

Tissue microarray

Human tissue microarray of normal and colon carcinoma samples were obtained from US Biomax (CO726, CO802, BC050112, CO811, CO801, CO482, CO701 and CO805). Immunohistochemical assay was conducted as described above with antibodies against DDB2 (Abcam). Tissues were counterstained with hematoxylin. Intensity of staining was blind scored from 0 (no staining) to 4 (highest intensity of staining). Graphs represent the average intensity of staining and paired t test of colon carcinoma versus normal colon scores of intensity of the staining.

siRNA transfection and Western blot analyses. The siRNA transfection and Western blot analyses were conducted following previously described procedures (28).

Cell culture. Human colon carcinoma cell lines were cultured in Dulbecco’s Modified Eagle Medium (HCT116) or RPMI-1640 (SW 480 and SW 620) medium supplemented with 10% FBS and penicillin/streptomycin. The cell lines were obtained from American Type Culture Collection, and were used within 6 months. We did not conduct any additional authentication after receiving the cell lines. Stable clones of HCT116 cells expressing control short hairpin RNA (shRNA) or DDB2 shRNA were selected using puromycin. Stable clones of SW620 cells expressing empty vector or vector expressing DDB2 were selected using G418.

RT-PCR assays. Semiquantitative real-time PCR assays were conducted following a previously described procedure (28). The primers have been described in the Supplementary Information.

Tumorigenicity and metastasis experiment. Tumorigenicity studies were carried out using mouse xenografts (30). For lung metastasis, 1 × 10⁶ cells were injected into the tail vein of 8 weeks old male nude mice. Four weeks after the injection, mice were euthanized by CO2 followed by cervical dislocation. Lung was removed and were fixed in 10% buffer formalin and paraffin embedded. Serial sections of lung tissue were made and examined by hematoxylin and eosin (H&E) staining. To study metastasis using an orthotopic model, 1 × 10⁶ cells were injected into the peritoneal cavity of immunocompromised severe combined immunodeficient (SCID) beige mice. The cells were allowed to grow into a tumor over the course of 2 weeks. This allowed a tumor of roughly a centimeter to grow and be dissected. Tumor sections were then taken and implanted on the cecum of a host SCID beige mouse using surgical glue. As the liver is the common first site of metastasis of colorectal cancer (CRC), the livers were examined after 4 weeks of implantation. Liver sections were stained with H&E. Micrometastases were then counted and statistically evaluated.

Chromatin immunoprecipitation assay

Chromatin immunoprecipitation (ChiP) experiments were carried out following a previously described procedure (28).

Results

DDB2 deficiency increases invasiveness and tumorigenicity of colon cancer cells

Analyses of the publicly available database revealed a downregulation of the Ddb2-mRNA in majority of the colon carcinoma datasets. Out of 30 available datasets, 24 datasets showed significant downregulation (Supplementary Fig. S1A). We confirmed the observation at the protein level by analyzing tissue microarrays from a commercial source (US Biomax) that contained samples corresponding to the various grades of colon cancer. Immunohistochemical staining of the samples revealed a strong correlation between the loss of DDB2 expression and the high-grade metastatic colon cancers (Fig. 1A and B and Supplementary Fig. S2). DDB2 is a nuclear protein (25). Therefore, we compared the nuclear signal intensities of DDB2 in our analyses of the tumor microarray. Matched normal colon and colon carcinoma tissues confirmed the observations (Supplementary
The high-grade specimens also exhibited a loss of E-cadherin expression (Fig. 1A and C). To further investigate the significance of DDB2 downregulation in colon cancer, we compared the colon cancer cell line HCT116 expressing control shRNA with that expressing DDB2-shRNA (Fig. 2A). First, the DDB2-shRNA–expressing HCT116 cells were found to be signiﬁcantly more invasive compared with the control cell line, as judged by Matrigel migration assay (Fig. 2B). The invasiveness was conﬁrmed also by scratch-healing assay (Supplementary Fig. S3A). Moreover, in soft agar colony formation assay, the DDB2-shRNA–expressing cells produced signiﬁcantly more colonies than the control HCT116 cells (Fig. 2C). The DDB2-deﬁcient cells were resistant to anoikis (Supplementary Fig. S3B). Consistent with that, the DDB2-deﬁcient cells showed higher expression of phospho-extracellular signal-regulated kinase and p-AKT compared with the normal cells (Supplementary Fig. S3B). To conﬁrm the increased tumorigenicity in the absence of DDB2, we compared tumor growth using mouse xenograft experiments. Two million HCT116 cells expressing control shRNA or DDB2-shRNA were injected into nude mice subcutaneously and tumor growth was measured. Clearly, the DDB2-deﬁcient cells generated a larger tumor mass in a much shorter time (Fig. 2D and E). That was evident also in a tumor growth curve analysis (Fig. 2F). The experiment in Fig. 2E was carried out with a different pair of HCT116-clones expressing shRNA against DDB2 or control. Also, polyclonal cells stably expressing shRNA for DDB2 formed greater number of soft agar colonies and aggressive xenograft tumors (Supplementary Fig. S4A and S4B).
DDB2 inhibits EMT of the colon cancer cells

Closer analyses of the DDB2 knockdown cells indicated a change in morphology of the cells. Unlike the epithelial cuboid appearance of the parental cells, the DDB2-deficient HCT116 cells exhibited elongated mesenchymal-like morphology, a change that is observed during EMT (Fig. 3A). Also, there was a clear loss of surface expression of E-cadherin and increase in expression of the mesenchymal markers vimentin in the DDB2-deficient cells (Fig. 3A and B). In Western blot assays (Fig. 3B), the E-cadherin level was decreased upon depletion of DDB2. Polyclonal cell line stably expressing shRNA for DDB2 also exhibited similar phenotype (Supplementary Fig. S5A and S5B). We further investigated whether DDB2 inhibits EMT of colon cancer cells.

Figure 2. DDB2 deficiency increases invasiveness and tumorigenicity of colon cancer cells. A, protein extracts from HCT 116 expressing control shRNA or DDB2-shRNA were subjected to Western blot analysis with DDB2 (50 μg protein) antibody. B, Transwell invasion assay of HCT116 cells expressing control shRNA or DDB2-shRNA (mean ± SD; n = 3). C, HCT116 cells expressing control shRNA or DDB2-shRNA were grown on soft agar for 10 days. Top, representative field of soft agar colonies. Bottom, the bar graph representing quantification of soft agar colonies (mean ± SD; n = 3). D, HCT116 cells expressing control shRNA or DDB2-shRNA were injected subcutaneously into nude mice. Representative picture of xenograft tumors induced in nude mice by HCT116 cells expressing control shRNA or DDB2-shRNA 7 weeks after inoculation (n = 5). E, bar graph representing tumor mass in nude mice from HCT116 cells expressing control shRNA or DDB2-shRNA at the point of sacrifice of the mice (mean ± SEM; n = 10). F, tumor volume induced in nude mice by HCT116 cells expressing control shRNA or DDB2-shRNA (n = 5). The asterisk in B, C, and E indicates statistically significant differences, with the following P value calculated by Student t test: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.
cells, in vivo. Analyses of the xenograft tumor sections revealed aggressive nature of the tumor from DDB2 knockdown cells, as evidenced by increased expression of SMA, vimentin, and PCNA, as well as reduced apoptosis (Fig. 3C and Supplementary Figs. S6 and S7). The increased proliferation, as judged by PCNA staining, most likely reflects increased angiogenesis that is induced by the mesenchymal-like cells (31). The tumor samples also exhibited a loss of E-cadherin expression (Fig. 3C).

Next, we compared the human colon cancer lines SW480 with SW620, which were derived from the same patient. SW480 corresponds to an early stage, whereas SW620 corresponds to a later metastatic stage (32). The SW620 cells are mainly mesenchymal, whereas SW480 cells are epithelial (33). Knockdown of DDB2 in the SW480 cells resulted in EMT-like morphologic changes of these cells (Fig. 4A). Moreover, expression of DDB2 in the SW620 cells increased population of cells with epithelial morphology (Fig. 4B). Interestingly, there was about a 3.5-fold decrease in the DDB2 expression during progression from SW480 to SW620 (Fig. 4C). Knockdown of DDB2 in the SW480 cells caused a significant reduction (about 5-fold) in the level of E-cadherin (Fig. 4D), whereas expression of DDB2 in the SW620 cells caused a significant increase in the epithelial phenotype, as measured by increased E-cadherin and reduced vimentin expression (Fig. 4E and F). Together, these observations suggest that DDB2 is a regulator of EMT in colon cancer cells.

To determine whether DDB2 inhibits EMT induced by TGF-β and hypoxia, we overexpressed DDB2 in SW480 cells. The cells were then subjected to treatments with TGF-β or hypoxia. Extracts of the treated cells were analyzed for expression of E-cadherin. Treatments with TGF-β or hypoxia caused an inhibition in the levels of E-cadherin in the SW480 cells, whereas the cells overexpressing DDB2 exhibited an attenuated inhibition of E-cadherin expression by TGF-β or hypoxia (Supplementary Fig. S8A and S8B). Unlike the TGF-β-treated cells, DDB2 expression did not inhibit the level of vimentin in the hypoxia-treated cell (Supplementary Fig. S8A), which is likely due to the shorter timeframe (24 hours instead of 48 hours) of the hypoxia experiment. The DDB2-expressing cells undergo apoptosis at the longer timepoints in hypoxia.
DDB2 transcriptionally represses expression of the genes that induce EMT

RNA expression analyses further confirmed that the DDB2-deficient cells express lower levels of the epithelial markers E-cadherin, cytokeratin 18, and cytokeratin 19 (Fig. 5A), and increased expression of the mesenchymal markers vimentin and N-cadherin (Fig. 5A). Several transcription factors, which have been implicated in the process of EMT such as Snail and Zeb 1, were upregulated at the mRNA level in the absence of DDB2 (Fig. 5A). VEGF is known to be an important player in the EMT process (18, 34). We observed significant increase in the level of VEGF in the DDB2 knockdown cells (Fig. 5A). Moreover, there was increased expression of Pinch 1, a protein that has been implicated in EMT (35). Also, siRNA-mediated knockdown of DDB2 in the SW480 cells increased expression of VEGF, Zeb1, and Snail (Fig. 5B and C). Furthermore, expression of DDB2 in the SW620 cells inhibited expression of VEGF, Snail, and Zeb1 (Fig. 5D and E).

Our previous studies on the regulation of the antioxidant genes by DDB2 identified a transcriptional repression function of DDB2. To examine whether DDB2 regulates expression of these genes directly, we carried out ChIP experiments to look at DDB2 occupancy at 3,000 bp upstream from the transcription start sites of these genes. The PCR amplicons on the 3 promoters are indicated schematically in Supplementary Fig. S9B. DDB2 interacted with the VEGF promoter in ChIP assays at 2 distinct sites (Fig. 6A). Moreover, DDB2 interacted with the Zeb1 and the Snail promoters at specific sites (Fig. 6B and C). The binding of DDB2 to those sites was confirmed further using a monoclonal antibody against the epitope tag T7 in ChIP experiments with cells expressing T7-tagged DDB2 (Supplementary Fig. S9). The DDB2-associated protein Cul4a binds to Suv39h, a histone H3K9 methyl transferase that participates in repression (28). Therefore, we examined whether DDB2 functions as a transcriptional repressor by recruiting Suv39h onto the promoters of VEGF, Zeb1, and Snail. ChIP was conducted with antibodies against DDB1, Cul4a, Suv39h, and H3K9Me3 using the HCT116 cells or the HCT116 cells expressing the DDB2-shRNA. There was no significant difference in the levels of these proteins between the 2 cell types (Supplementary Fig. S11). The ChIP-DNAs were probed for VEGF (probe set V), Zeb1 (probe set VIII), and Snail (probe set IX), and the bindings in the HCT116 control cells were compared with those in the
HCT116-DDB2shRNA cells. Clearly, there was reduced occupancy of DDB1, Cul4a, and Suv39h on the promoter of all 3 genes in the cells expressing shRNA for DDB2 (Fig. 6D). Consistent with that, those cells also exhibited a reduced H3K9Me3 interaction with the promoters (Fig. 6D). Although we used a semiquantitative method to assess the binding, the results presented are averages from 3 different batches of chromatin preparations. There was also an increase in the histones H3 and H4 acetylation in the HCT116-DDB2-shRNA cells (Fig. 6E). Previously, it was shown that the NER factors assemble with RNA polymerase II on the promoter involving the XPC protein (36). However, we did not detect association of XPC with the DDB2 interaction sites in the promoters of VEGF, Snail, and Zeb1 (Fig. 6F). Together, the observations suggest that DDB2 recruits Suv39h through its interaction with Cul4a to bring about histone H3K9 trimethylation in the promoters of VEGF, Zeb1, and Snail, leading to repression.

**DDB2 regulates metastasis of colon cancer cells**

Next, we conducted functional metastasis assays to examine whether the DDB2 knockdown cells are more metastatic. First, we carried out metastasis experiment using an orthotopic mouse model. The control HCT116 or the DDB2 knockdown HCT116 cells were subcutaneously injected into SCID beige mice. Once the tumors reached 0.5 mm in diameter, the tumors were excised, and pieces of tumors were surgically implanted onto the cecum of host mice. Four weeks following implantation, the mice were analyzed for metastatic growth in the liver. We observed extensive metastasis with the tumor generated from the DDB2 knockdown cells in the liver (Fig. 7A). The tumor implant generated with the control HCT116 cells did not undergo any visible metastasis in any organ under these experimental conditions.

To further confirm the observation, we conducted tail vein injection of the DDB2-depleted cells in athymic nude mice. The parental or the DDB2 knockdown cells were injected into the tail vein of mice. To detect acceleration of metastasis by the loss of DDB2, we looked at the lung tumor metastasis after 4 weeks. The mice were sacrificed and examined for lung nodules. The mice injected with the DDB2 knockdown cell line clearly exhibited evidence of lung tumor micrometastasis within that time, whereas the control HCT116-injected mice...
Figure 6. DDB2 epigenetically regulates expression of VEGF, Zeb1, and Snail. A–C, HCT116 cells were subjected to ChIP assays on VEGF, Zeb1, or Snail promoter. Two microgram antibody against DDB2 or immunoglobulin G (IgG) was used for immunoprecipitation. D, HCT116 cells expressing control shRNA or DDB2-shRNA were subjected to ChIP assays using 2 μg antibody against Cul4a, DDB1, Suv39h, H3K9Me3, or IgG. The VEGF, Zeb1, and Snail promoter fragments in the immunoprecipitated chromatin were quantified with the primer pairs V (for VEGF), VIII (for Zeb1), and IX (for Snail). Bar graph represents immunoprecipitation as percentages to the input material (mean ± SD; n = 3) normalized to IgG control. E, HCT116 cells expressing control shRNA or DDB2-shRNA were subjected to ChIP assays using 2 μg antibody against Cul4a, DDB1, Suv39h, H3K9Me3, or IgG. The VEGF, Zeb1, and Snail promoter fragments in the immunoprecipitated chromatin were quantified with the primer pairs V (for VEGF), VIII (for Zeb1), and IX (for Snail). Bar graph represents immunoprecipitation as percentages to the input material (mean ± SD; n = 3) normalized to IgG control.
exhibited fewer micrometastatic nodules (Fig. 7B). Polyclonal cells stably expressing shRNA for DDB2 also exhibited increased metastatic frequency (Supplementary Fig. S12). Because expression of DDB2 inhibited expression of the EMT genes and blocked EMT, we sought to determine whether expression of DDB2 inhibits metastasis. To investigate that, we compared the metastatic line SW620 with SW620 stably expressing DDB2. Expression of DDB2 had only marginal effects on the proliferation of the SW620 cells, in vitro (Supplementary Fig. S13). Cells were injected into nude mice via tail vein. Six weeks following injection, the mice were sacrificed and the metastatic colonies in the lung were compared. There was a significant reduction in the metastatic colonies in the lung tissue from mice injected with DDB2-expressing SW620 cells (Fig. 7C). These observations provide evidence that DDB2 is a potent inhibitor of colon cancer metastasis.

**Discussion**

The work presented here is significant in several ways. First, the observations show a role of DDB2, an NER protein, in the regulation of colon cancer metastasis. We show that it is a potent regulator of EMT, as it transcriptionally inhibits expression of the key genes required for EMT and tumor invasion (Fig. 7D). Moreover, we show that DDB2 stands as a barrier downstream of the signaling pathways that induce EMT. Together, the results identify a new tumor suppression function of DDB2 that inhibits metastasis of colon cancers.

Mutations in the nucleotide repair genes are rare in CRC. However, in a study with small groups of patients with CRC, it was shown that 25% (2/8) exhibited LOH at the XPE loci, 11q12-13 (37). Our analyses of the publicly available database indicated a reduced expression of DDB2 in a much greater population of the patients with CRC. Moreover, the reduction of DDB2 expression coincides with the appearance of high-grade colon cancers. Therefore, progression of colon cancer associates with the activation of mechanisms that reduce DDB2 expression. It is noteworthy that DDB2 is a p53-induced gene (38), and p53 mutations are common in colon cancer, and that might explain the loss of expression. The loss of DDB2 expression is expected also to reduce the repair (NER) activity, which may contribute to the evolution of the high-grade colon cancer. In this study, however, we show that the transcriptional repressor function of DDB2 regulates EMT. The observation that DDB2 inhibits EMT, and overexpression of DDB2 could reverse the mesenchymal phenotype to epithelial phenotype, could not be explained by its NER activity. Moreover, expression of DDB2 inhibited the metastatic activity of the SW620 cells, which could not be explained by its NER function. Transcriptional repression of VEGF, Snail, and Zeb1 expression, on the other hand, will readily explain the inhibitions of EMT and metastasis.

DDB2 was shown to bind the Sod2 gene promoter through a specific sequence element and constitutively repress that gene (29). However, we observed that DDB2 could repress expression of the Catalase gene in the absence of that sequence element (28). Therefore, we suspect that, in addition to sequence-specific binding, DDB2 functions also as a corepressor through interactions with other DNA-binding factors. Previously, we showed that the association of DDB2 induced an increase in the histone H3K9 trimethylation of the Sod2 and the Catalase promoters, leading to transcriptional repression (28). In this study, we observed a similar phenomenon. For example, DDB2 enhanced the recruitment of Cul4, DDB1, and Suv39h onto the promoters of VEGF, Snail, and Zeb1. Recruitment of Suv39h, a histone H3K9 methyl transferase, correlated with an increase in H3K9-trimethylation of the target genes. Expression of DDB2-shRNA inhibited the interaction of Suv39h, coinciding with a reduction in the levels of H3K9-trimethylation (Fig. 6). The ChIP regions in the VEGF, Snail, and Zeb1 promoters contain anywhere between 30 and 50 DNA elements corresponding to sequence-specific DNA-binding proteins, and a large number of them are present in all 3 promoters (see Supplementary Fig. S10A). Therefore, it remains possible that DDB2 is recruited to these promoters through interactions with one or more DNA-binding proteins that commonly regulate these promoters. Nonetheless, our observations indicate a clear role of DDB2 in the constitutive repression of the EMT genes, involving H3K9 trimethylation of the promoters of VEGF, Snail1, and Zeb1.

The decrease in expression of DDB2 was observed also in the colon cancer cell line SW620 compared with SW480. These 2 lines are derived from one patient at an early point in the tumor progression, SW480, and at a later metastatic stage of progression, SW620 (32). Both lines harbor the same mutation in the DNA-binding domain of p53 (39). It is noteworthy that DDB2 expression is not completely dependent upon p53 because other mechanisms could increase its expression in p53−/− cells (28, 40). Therefore, it is not surprising that the SW480 cells express DDB2 at a higher level compared with the SW620 cells. Interestingly, re-expression of DDB2 in the SW620 cells induced expression of the epithelial markers associated with inhibition of the mesenchymal morphology. These observations also indicate that DDB2 is one of the major regulators in epithelial tumor cells that resist conversion to a mesenchymal-like morphology, and that induction of EMT occurs mainly after a loss of DDB2 expression. Consistent with that, we show that a reduced expression of DDB2 enhances metastasis of colon cancer cells in both experimental metastasis assays and in an orthotopic xenograft model. Moreover, re-expression of DDB2 inhibits metastasis. Taken together,
Figure 7. DDB2 regulates metastasis of colon cancer cells. A, HCT116 cells expressing control shRNA or DDB2-shRNA were injected subcutaneously into SCID beige mice. Once xenografts were established, they were excised and orthotopically implanted into other SCID beige mice using microsurgical techniques ($n = 3$). Animals were sacrificed 4 weeks after implantation and examined for liver metastasis. Representative H&E staining of liver sections from mice injected with HCT116 cells expressing control shRNA or DDB2-shRNA are shown (left). Quantification of percentage of metastasis occurrence in mice injected with HCT116 cells expressing control shRNA or DDB2-shRNA are shown (right). B, HCT116 cells expressing control shRNA or DDB2-shRNA were injected into 8 weeks old male nude mice intravenously via the tail vein ($n = 3$). Mice were sacrificed after 4 weeks and lung tissues were harvested. Representative H&E staining of lung from mice injected with HCT116 cells expressing control shRNA or DDB2-shRNA (left). Quantification of percentage of micrometastasis occurrence in mice injected with HCT116 cells expressing control shRNA or DDB2-shRNA are shown (right). C, SW620 cells expressing empty vector or DDB2-expressing vector were injected into 8 weeks old male nude mice intravenously via tail vein ($n = 3$). Mice were sacrificed after 6 weeks and lung tissues were harvested. Representative H&E staining of lung from mice injected with SW620 cells expressing empty vector or DDB2-expressing vector (left). Quantification of percentage of metastasis occurrence in mice injected with SW620 cells expressing empty vector or DDB2-expressing vector (right). Scale bar for all the images, 10 μm. D, schematic diagram indicating the mechanism by which DDB2 inhibits EMT. EMT-inducing signals (hypoxia or TGF-β) increases expression of VEGF, Snail1, and Zeb1 to reduce expression of E-cadherin and bring about EMT-like changes in colon cancer cells. The XPE gene product DDB2, on the other hand, binds to the promoters of VEGF, Snail1, and Zeb1 to reduce expression of E-cadherin and supports MET.
the results presented here explain why loss of DDB2 expression coincides with the high-grade progression of colon cancers. Moreover, the results for the first time, show an important tumor suppression function of the xeroderma pigmentosum gene DDB2 in colon cancer metastasis.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors' Contributions
Conception and design: N. Roy, D. Kopanja, S. Bagchi, P. Raychaudhuri
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): N. Roy, P.V. Bommi, U.G. Bhat, J. Li, K.C. Patra, A. Blumier, R.V. Benya, S. Bagchi
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): N. Roy, S. Bagchi, P. Raychaudhuri
Writing, review, and/or revision of the manuscript: N. Roy, R.V. Benya, P. Raychaudhuri
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Bhattacharjee, I. Elangoovan, J. Li, R.V. Benya
Study supervision: S. Bagchi, P. Raychaudhuri

Grant Support
This work was supported by grants from the National Cancer Institute to P. Raychaudhuri and S. Bagchi (CA77637 and CA 156164).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 27, 2012; revised April 7, 2013; accepted April 9, 2013; published OnlineFirst April 22, 2013.

References


DDB2 Suppresses Epithelial-to-Mesenchymal Transition in Colon Cancer


Cancer Res  Published OnlineFirst April 22, 2013.